Description

LGD-4033 Powder (Ligandrol) – Industrial Grade Bulk Supply

 

Product Details Table

 

---

LGD-4033 (Ligandrol) Powder | High-Potency SARM for Androgen Receptor Research | BioSynLab

BioSynLab presents pharmaceutical-grade LGD-4033 (Ligandrol) in micronized powder form for advanced androgen receptor research, formulation development, and large-scale analytical studies. As one of the most potent non-steroidal SARMs documented in preclinical literature, Ligandrol powder offers maximum flexibility for custom formulation preparation, dose-response studies, and institutional-scale research programs.

Chemical Architecture & Superior Potency

LGD-4033 (Ligandrol, VK5211) maintains the same exceptional pharmacological profile as our capsule formulation, now in versatile powder presentation:

Structural Features:

• Quinoline Core: Fused bicyclic aromatic system for optimal AR binding
• Dual Trifluoromethyl Groups: CF₃ substituents enhancing metabolic stability
• Pyrrolidine Ring: Five-membered nitrogen heterocycle for binding specificity
• Amide Linkage: Critical pharmacophore for hydrogen bonding

Mechanism of Action:

• High-Affinity AR Agonist: Ki ~1 nM (highest affinity among commercial SARMs)
• Tissue Selectivity: Anabolic effects in muscle/bone, minimal androgenic activity
• Superior Potency: Significantly more potent than first-generation SARMs
• Oral Bioavailability: Excellent systemic exposure

Physicochemical Properties:

• Molecular weight: 338.25 g/mol
• Calculated LogP: 3.6 (optimal lipophilicity)
• Melting point: 105-110°C (crystalline solid)
• Chirality: Single enantiomer (>99% ee)

Powder Engineering & Research Advantages

Our micronized LGD-4033 powder (20-50μm) offers distinct advantages for advanced research:

Solubility Profile:

• Dimethyl sulfoxide (DMSO): ≥100 mg/mL (preferred stock solvent)
• Ethanol: ≥80 mg/mL (very good)
• Methanol: ≥90 mg/mL (excellent)
• Acetonitrile: ≥70 mg/mL (good)
• Water: <1 mg/mL (requires co-solvent)
• PEG-400: ≥60 mg/mL (formulation compatible)

Stock Solution Preparation:

• 10 mM DMSO stock: Dissolve 3.38mg in 1mL anhydrous DMSO
• Storage: -80°C in aliquoted portions
• Working solutions: Prepare fresh daily in aqueous buffers

Powder Handling Properties:

• Flowability: Excellent (Carr index <15)
• Compressibility: Suitable for tablet formulation research
• Hygroscopicity: Low (stable under ambient conditions)
• Electrostatic charge: Minimal (anti-static processing)

Formulation Flexibility:

• Custom capsule preparation (research formulation development)
• Suspension formulation (aqueous vehicles)
• Transdermal delivery research (liposomal formulations)
• Injectable formulations (sterile solution preparation)

Analytical Characterization & Quality Verification

Each BioSynLab LGD-4033 powder batch undergoes comprehensive analytical profiling:

Chromatographic Analysis:

• HPLC-UV (220nm): ≥99.0% purity
• Chiral HPLC: Enantiomeric purity >99% ee
• Related substances: <1.0% total impurities
• Residual solvents: Meets ICH Q3C

Mass Spectrometry:

• LC-MS/MS: [M+H]⁺ at m/z 339.1
• High-Resolution MS: Exact mass <3 ppm deviation

Nuclear Magnetic Resonance (NMR):

• ¹H NMR (600MHz, DMSO-d₆): Complete structural assignment
• ¹⁹F NMR: Two distinct CF₃ signals
• ¹³C NMR (150MHz): 14 distinct carbon signals
• FTIR: Amide N-H (3300 cm⁻¹), C=O (1680 cm⁻¹), C-F (1120 cm⁻¹)

Physical Testing:

• Water content: <0.3% (Karl Fischer)
• Heavy metals: <5 ppm (ICP-MS)
• Specific rotation: [α]²⁰D = +8° to +12°
• Particle size: Laser diffraction confirmed (20-50μm)
• Bulk density: 0.4-0.6 g/cm³

Research Applications & Scientific Significance

LGD-4033 powder serves expanded research functions:

Formulation Development:

• Novel delivery systems (nanoparticles, liposomes)
• Bioavailability enhancement (solubilization techniques)
• Controlled release formulations (polymeric matrices)
• Stability studies (forced degradation, ICH Q1A)

Androgen Receptor Pharmacology:

• Ultra-high affinity binding (sub-nanomolar Ki)
• Crystal structure investigations (AR LBD co-crystallization)
• Coactivator recruitment (SRC-1, GRIP1, p/CIP)
• Tissue selectivity profiling

Musculoskeletal Research:

• Severe muscle atrophy models (cancer cachexia, COPD)
• Hip fracture recovery (elderly populations)
• Glucocorticoid-induced myopathy
• Sarcopenia interventions

Comparative SARM Research:

• Potency comparisons (LGD-4033 vs. MK-2866 vs. RAD-140)
• Structure-activity relationships
• Selectivity profiling (prostate vs. muscle ratios)
• Combination studies

Global Distribution & Discrete Procurement

BioSynLab provides secure, compliant distribution:

Packaging Specifications:

• Primary: Amber Type I borosilicate glass (5-100mL)
• Secondary: Argon-flushed aluminized barrier pouch
• Tertiary: Discrete unmarked shipping containers

Shipping Options:

• Standard: Ambient temperature, 5-7 days
• Refrigerated: 2-8°C for extended stability
• Express: Tracked courier, 2-3 days
• Discrete: No product identifiers, generic return addresses

Bulk Orders:

• Kilogram-scale: Available for institutional programs
• Batch consistency: Inter-batch RSD <2%
• Custom synthesis: Available upon request

Service Coverage:

United Kingdom: London, Manchester, Birmingham, Leeds, Glasgow, Liverpool, Sheffield, Bristol, Edinburgh, Cardiff, Belfast, Nottingham, Leicester.

European Union: Berlin, Hamburg, Munich, Cologne, Frankfurt, Amsterdam, Rotterdam, Paris, Lyon, Barcelona, Madrid, Rome, Milan, Vienna, Brussels, Prague, Warsaw.

North America: New York, Los Angeles, Chicago, Houston, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Toronto, Vancouver.